ES3065261T3 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof - Google Patents

Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Info

Publication number
ES3065261T3
ES3065261T3 ES20862121T ES20862121T ES3065261T3 ES 3065261 T3 ES3065261 T3 ES 3065261T3 ES 20862121 T ES20862121 T ES 20862121T ES 20862121 T ES20862121 T ES 20862121T ES 3065261 T3 ES3065261 T3 ES 3065261T3
Authority
ES
Spain
Prior art keywords
crystalline form
pyridin
compound
cancer
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20862121T
Other languages
English (en)
Spanish (es)
Inventor
Franck Raeppel
Stephane Raeppel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Application granted granted Critical
Publication of ES3065261T3 publication Critical patent/ES3065261T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES20862121T 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof Active ES3065261T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962898469P 2019-09-10 2019-09-10
PCT/US2020/049986 WO2021050580A1 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
ES3065261T3 true ES3065261T3 (en) 2026-05-05

Family

ID=74866002

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20862121T Active ES3065261T3 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Country Status (7)

Country Link
US (1) US12466838B2 (cg-RX-API-DMAC7.html)
EP (1) EP4027999B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022546861A (cg-RX-API-DMAC7.html)
CN (1) CN114401720A (cg-RX-API-DMAC7.html)
CA (1) CA3150267A1 (cg-RX-API-DMAC7.html)
ES (1) ES3065261T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021050580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
CN107646030A (zh) * 2015-08-19 2018-01-30 桑多斯股份公司 丙二酸酯衍生物的不对称双酰胺化
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物

Also Published As

Publication number Publication date
CA3150267A1 (en) 2021-03-18
JP2025102940A (ja) 2025-07-08
US20220402936A1 (en) 2022-12-22
JP2022546861A (ja) 2022-11-09
EP4027999A4 (en) 2023-08-16
WO2021050580A1 (en) 2021-03-18
EP4027999A1 (en) 2022-07-20
EP4027999C0 (en) 2026-03-04
CN114401720A (zh) 2022-04-26
US12466838B2 (en) 2025-11-11
EP4027999B1 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
IL290106B1 (en) Crystalline form of ATR inhibitor and its use
IL274027A (en) B-RAF kinase inhibitor salt crystals
PL3915989T3 (pl) Inhibitor jak i sposób jego otrzymywania
IL288062A (en) Crystalline forms of tapamidis and its salts
EP3283486A4 (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
PT3894012T (pt) Formas cristalinas e formas salinas de um inibidor de cinase
EP3372607A4 (en) Crystalline form of btk kinase inhibitor and preparation method thereof
EP3216790A4 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
ZA202109737B (en) Compound used as kinase inhibitor and application thereof
IL267393A (en) Crystal forms of a Janus kinase inhibitor
GB202101909D0 (en) Novel crystalline form of pyroxa-sulfone, methods for its preparation and use of the same
IL288484A (en) Crystalline salt forms of a kinase inhibitor
IL289453A (en) Process for the preparation of ridinilazole and crystalline forms thereof
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
EP3255046A4 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
EP3677575A4 (en) CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
EP4027999C0 (en) CRYSTALLINE FORM OF A MULTIPLE TYROSINE KINASE INHIBITOR, ITS PREPARATION PROCESS AND ITS USE
GB201918391D0 (en) Novel crystalline forms of flufenacet, methods for their preparation and use of the same
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
PL3553060T3 (pl) Polikrystaliczny mesylan inhibitora fosfodiesterazy typu 5, sposób jego przygotowania i jego zastosowanie
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
GB201912411D0 (en) Crystalline forms of ivosidenib
EP3699177A4 (en) METHOD OF MANUFACTURING A TYROSINKINAS INHIBITOR AND INTERMEDIATE THEREOF